Phase II study of durvalumab plus tremelimumab as therapy for patients with previously treated anti-PD-1/PD-L1 resistant stage IV squamous cell lung cancer (Lung-MAP substudy S1400F, NCT03373760)

First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial

(2021) Paul Baas et al.   LANCET

Pembrolizumab Plus Ipilimumab or Placebo for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%: Randomized, Double-Blind Phase III KEYNOTE-598 Study

(2021) Michael Boyer et al.   JOURNAL OF CLINICAL ONCOLOGY

Impact of DNA damage response and repair (DDR) gene mutations on efficacy of PD-(L)1 immune checkpoint inhibition in non-small cell lung cancer

(2020) Biagio Ricciuti et al.   CLINICAL CANCER RESEARCH

Efficacy of immunotherapy in lung cancer with co-occurring mutations in NOTCH and homologous repair genes

(2020) Marco Mazzotta et al.   Journal for ImmunoTherapy of Cancer

Biomarker-driven therapies for previously treated squamous non-small-cell lung cancer (Lung-MAP SWOG S1400): a biomarker-driven master protocol

(2020) Mary W Redman et al.   LANCET ONCOLOGY

SWOG S1400D (NCT02965378), a Phase II Study of the Fibroblast Growth Factor Receptor Inhibitor AZD4547 in Previously Treated Patients With Fibroblast Growth Factor Pathway–Activated Stage IV Squamous Cell Lung Cancer (Lung-MAP Substudy)

(2019) Charu Aggarwal et al.   Journal of Thoracic Oncology

Brief Report: SWOG S1400B (NCT02785913), A Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)

(2019) Corey J. Langer et al.   Journal of Thoracic Oncology

Brief Report: SWOG S1400C (NCT02154490)—A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-study)

(2019) Martin J. Edelman et al.   Journal of Thoracic Oncology

Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer

(2019) Matthew D. Hellmann et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma

(2018) Robert J. Motzer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety and activity of durvalumab + tremelimumab in immunotherapy (IMT)-pretreated advanced NSCLC patients.

(2018) Edward B. Garon et al.   JOURNAL OF CLINICAL ONCOLOGY

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

(2016) Roy S Herbst et al.   LANCET

Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study

(2016) Scott Antonia et al.   LANCET ONCOLOGY

Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints

(2016) Shohei Koyama et al.   Nature Communications

Lung Master Protocol (Lung-MAP)--A Biomarker-Driven Protocol for Accelerating Development of Therapies for Squamous Cell Lung Cancer: SWOG S1400

(2015) R. S. Herbst et al.   CLINICAL CANCER RESEARCH

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

(2015) Julie Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

(2015) Hossein Borghaei et al.   NEW ENGLAND JOURNAL OF MEDICINE

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

(2015) James Larkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

(2015) N. A. Rizvi et al.   SCIENCE

Combination immunotherapy approaches

(2012) C. G. Drake   ANNALS OF ONCOLOGY

PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors

(2010) M. A. Curran et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA